

## **FORM 7**

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: Psyence Group Inc. (the "Issuer").

Trading Symbol: PSYG

Number of Outstanding Listed Securities: 85,528,931

Date: March 1, 2022

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

During the month of February 2022, the Issuer continued general and corporate operations as well as strategic initiatives.

Psyence Group Inc. (the "**Company**") is a public life science biotechnology company listed on the Canadian Securities Exchange and (CSE: PSYG) and quoted on the OTCQB (OTCQB: PSYGF), with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

On February 9, 2022 the Issuer announced that the Company's common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States ("US").

DTC is a subsidiary of the Depository Trust & Clearing Corp., which manages the electronic clearing and settlement of publicly traded companies in the US. DTC eligibility incorporates an electronic method of clearing securities that accelerates the receipt of stock and cash, reduces costs, and allows the stock to be traded over a much wider selection of brokerage firms by meeting their clearing and settlement requirements.

The Company's cultivation facility in Lesotho, Southern Africa recently completed a stage 1 audit of the facility conducted by the British Standards Institute against the assessment standard ISO 22000:2018.

On February 7, 2022 the Issuer announced that its ISO22000 graded Psilocybin production facility has officially received International Organization for Standardization (ISO) 22000:2018 certification, awarded through the British Standards Institute (BSI). ISO 22000 is a globally accepted international standard that specifies the requirements for food safety management systems.

On February 16, 2022, the board of the Issuer resolved to amend the Issuer's Restricted Share Unit Plan, effective March 1, 2022, which amended and restated plan has been filed on SEDAR.

2. Provide a general overview and discussion of the activities of management.

During the month of February 2022, management continued to support and control the Issuer's business activities, develop the business and explore strategic business relationships.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

No new products or services have been developed and offered to the market in the past month.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

No products or services were discontinued during the reporting period.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

No new business relationships were entered into during the period.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

On February 17, 2022, MDK Advisory & Consulting Ltd tendered its resignation as the company secretary of the Issuer's Jamaican subsidiary, Psyence Jamaica Ltd, effective March 1, 2022. No further contracts were terminated during the period.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

The Issuer continues to file trademark applications in jurisdictions of interest with respect to its joint venture functional mushroom product *GOODMIND*.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
None	N/A	N/A	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers or committee members.

Deika Morrison resigned as a director of the Issuer's Jamaican subsidiary, Psyence Jamaica Ltd effective February 17, 2022.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Positive media coverage in February 2022 continues to shift consumer and public perception about the psychedelics industry in a matter which is favorable to the Issuer. Please see as a reference, the articles below. Demand for access to psilocybin, including in the area of palliative care is being positively reported on:

<https://microdose.buzz/news/johns-hopkins-study-shows-psilocybin-effective-for-a-year/>

[https://www.instagram.com/p/CaKAtq0suCi/?utm\\_medium=share\\_sheet](https://www.instagram.com/p/CaKAtq0suCi/?utm_medium=share_sheet)

<https://www.reuters.com/legal/litigation/magic-mushrooms-face-legal-test-2022-02-10/>

Other than the above, no new trends noted during the reporting period.

## Certificate of Compliance

The undersigned hereby certifies that:

- The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

## FORM 7 – MONTHLY PROGRESS REPORT

February 2022  
Page 5

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 01, 2022

Warwick Corden-Lloyd  
Name of Director or Senior  
Officer

(signed) "Warwick Corden-Lloyd"  
Signature

Chief Financial Officer  
Official Capacity

<b><i>Issuer Details</i></b>		For Month End	Date of Report
Name of Issuer Psyence Group Inc.		February 2022	YY/MM/D 22/03/01
Issuer Address 121 Richmond Street West, Penthouse Suite 1300			
City/Province/Postal Code Toronto, Ontario, M5H 1K1	Issuer Fax No. ( )	Issuer Telephone No. +1 416-477-1708	
Contact Name Warwick Corden-Lloyd	Contact Position CFO	Contact Telephone No. +1 416-477-1708	
Contact Email Address <a href="mailto:warwick@psyence.com">warwick@psyence.com</a>	Web Site Address <a href="https://www.psyence.com">https://www.psyence.com</a>		

## FORM 7 – MONTHLY PROGRESS REPORT